Navigation Links
NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
Date:3/7/2009

upport for continuing to develop NVC-422 for fungal infections."

NVC-422 is the most advanced of a series of compounds from a new class of drugs that mimics the body's natural defense against infection. NVC-422 may deliver the same or better efficacy as currently used antibiotics without contributing to the growing rise of bacterial resistance. The Company plans to file an exploratory Investigational New Drug application with the U.S. Food and Drug Administration in the second quarter of 2009 and initiate a Phase II clinical trial of NVC-422 during the second half of 2009 for impetigo, one of the most common skin infections among children, which produces blisters or sores on the face, neck, hands and diaper area.

"The ability to treat infection with a non-antibiotic is more important than ever because of the rise of drug resistant bacteria," said Dr. Ron Najafi, chairman and chief executive officer of NovaBay. "In developing anti-infective compounds, experience shows that preclinical results are more predictive of clinical efficacy than in other therapeutic categories, and I am encouraged that our preclinical work to date strongly suggests that NVC-422 may be a potent and well-tolerated treatment for numerous serious skin infections such as acne, nail fungus and topical viral infections, where antibiotics are not effective. Advancing NVC-422 into Phase II clinical trials reinforces the strength of our extensive preclinical work and, significantly, redefines NovaBay as a mid-stage biotech company."

NovaBay's experienced researchers have created a pipeline and research and development engine of first-in-class, broad-spectrum anti-bacterial and anti-fungal agents with low to no microbial resistance. In-vitro studies to date have shown that NVC-422 has a potentially expansive therapeutic utility against bacteria of all types, including multidrug resistant species; shedding viruses including adenoviruses; and
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
3. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
4. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
5. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
6. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
9. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
10. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
11. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...   3D Systems   (NYSE: DDD ) ... , a new robotic surgery skills and procedural training simulator, ... ERUS exhibition in Amsterdam, The Netherlands ... minimally invasive surgery represents a growing portion of overall surgical ... for robotic surgery has increased, and it is expected that ...
(Date:9/18/2014)...  Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment ... the Company,s Board of Directors, effective September 12, 2014. ... the Board of seven members. Dr. Altstiel will also ... and a member of the Audit and Compensation Committees ... Scientific Advisory Board, a position he has held since ...
(Date:9/18/2014)... , Sept. 18, 2014 Australian biomarker discovery ... US trial of its MiStat™ prostate cancer screening test, ... regulatory approval upon completion. Minomic,s proprietary MiStat™ ... presence of a proprietary biomarker known as the MIL-38 ... prostate cancer cells. Researchers at 11 ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... EATONTOWN, N.J. , Jan. 14 Osteotech, Inc. (Nasdaq: ... products for regenerative healing, today reported preliminary unaudited revenue for the ... $24.6 million for the same period in 2008.  During ... revenue from sales of its new innovative products all currently in ...
... and NORTH BRUNSWICK, N.J. , Jan. 14 ... that they have achieved the initial milestone of a research ... vitro test for potential allergic reactions to substances that could ... "Allergy Test on a Chip™," is intended to comprise a ...
Cached Medicine Technology:Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 2Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 3Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 4L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 2L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 3
(Date:9/18/2014)... September 18, 2014 Companies in the ... carbon dioxide, selling it to downstream industries in either ... carbon dioxide are food and beverage manufacturers. Food producers ... fruits, vegetables or pizzas. The gas is also used ... the compound to carbonate soft drinks, beer and other ...
(Date:9/18/2014)... supplements of selenium or vitamin E don,t seem ... men, a new study indicates. Previous animal research ... cataracts. To investigate this further, William Christen, from Brigham ... and his colleagues examined data from a randomized, placebo-controlled ... initially designed to study prevention of prostate cancer. ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading ... and co-founder John Cassimatis was named as one ... 2014, recognizing the region’s top healthcare and life ... of the year. , The Innovation Awards celebrate ... continue to shape the medical industry in Greater ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Stealth ... and wellness advocate, and Frank Davis, founder of ... Whole-food Nutrition, are pleased to announce the new ... to make delicious, nutrition-packed meals using Activz whole-food ... the next step in the Stealth Health ...
(Date:9/18/2014)... expect to pay higher employee contributions for their health ... officers about the impact of the Patient Protection and ... conducted by the Darla Moore School of Business at ... Patrick Wright, a professor in strategic human resource management, ... Officers. The survey is distributed to more than 560 ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3
... director of chemical and food safety programs with Pew Health ... response to the introduction of the Food Safety Modernization Act ... , "In the midst of an ongoing peanut product recall, ... not be more timely. The FSMA contains key improvements that ...
... The Greater Baltimore Committee is seeking nominations for ... Thursday, March 12, 2009. Those interested in nominating a ... . The four award categories are: Entrepreneurial, Best New ... Nominators will be asked to submit documentation and narratives ...
... Feb. 4 Speaker Nancy Pelosi and parents and children ... a photo opportunity this morning before the final House vote ... this afternoon. Below are the Speaker,s remarks and answer to ... in the House of Representatives and in the Congress of ...
... architect of BurrellesLuce 2.0, will be the featured speaker at the ... of America. , ... Livingston, NJ (PRWEB) February 4, 2009 -- Jeffrey ... , will be the featured speaker at the Feb. 11th luncheon ...
... Compuware Corporation (Nasdaq:, CPWR ) today announced ... Health,Initiative with a collaborative network for the secure ... The VIP Health,Initiative was formed by Scripps Mercy ... to enhance the quality of care,delivered while also ...
... Saturday, February 7 -- 8 a.m. - 3 p.m.DETROIT, Feb. ... more to smile about.With the help of dentists, dental hygienists, ... School of Dentistry will provide free oral health care ... Saturday, Feb. 7 from 8 a.m. to 3 p.m. on ...
Cached Medicine News:Health News:Statement From Pew Health & Human Services Policy Program on the Introduction of the Delauro Food Safety Modernization Act 2Health News:GBC Seeks Nominations for Fourth Annual Bioscience Awards 2Health News:Pelosi: 'Today is a Very Special Day for Us in the House; We Are Going to Help 11 Million Children' 2Health News:BurrellesLuce IT Expert to Explore Web 3.0's Potential PR Impact At February Luncheon Meeting of Westchester/Fairfield PRSA 2Health News:BurrellesLuce IT Expert to Explore Web 3.0's Potential PR Impact At February Luncheon Meeting of Westchester/Fairfield PRSA 3Health News:Compuware Covisint to Network VIP Health Initiative and Its Physicians, Enabling Improved Collaboration, Better Care 2Health News:Compuware Covisint to Network VIP Health Initiative and Its Physicians, Enabling Improved Collaboration, Better Care 3Health News:UDM School of Dentistry 'Gives Kids A Smile' 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: